Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients

Imagem de Miniatura
Arquivos
art_MOURA_Assessment_of_avidity_related_to_IgG_subclasses_in_2021.PDF (1.49 MB)
Citações na Scopus
39
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PORTFOLIO
Autores
MOURA, Andrew D.
COSTA, Hernan H. M. da
CORREA, Victor A.
LIMA, Ana K. de S.
GASPARI, Elizabeth De
HONG, Marisa A.
CUNHA-JUNIOR, Jair P.
PRUDENCIO, Carlos R.
Citação
SCIENTIFIC REPORTS, v.11, n.1, article ID 17642, 13p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
SARS-CoV-2 is considered a global emergency, resulting in an exacerbated crisis in the health public in the world. Although there are advances in vaccine development, it is still limited for many countries. On the other hand, an immunological response that mediates protective immunity or indicates that predict disease outcome in SARS-CoV-2 infection remains undefined. This work aimed to assess the antibody levels, avidity, and subclasses of IgG to RBD protein, in symptomatic patients with severe and mild forms of COVID-19 in Brazil using an adapted in-house RBD-IgG ELISA. The RBD IgG-ELISA showed 100% of specificity and 94.3% of sensibility on detecting antibodies in the sera of hospitalized patients. Patients who presented severe COVID-19 had higher anti-RBD IgG levels compared to patients with mild disease. Additionally, most patients analyzed displayed low antibody avidity, with 64.4% of the samples of patients who recovered from the disease and 84.6% of those who died in this avidity range. Our data also reveals an increase of IgG1 and IgG3 levels since the 8th day after symptoms onset, while IgG4 levels maintained less detectable during the study period. Surprisingly, patients who died during 8-14 and 15-21 days also showed higher anti-RBD IgG4 levels in comparison with the recovered (P < 0.05), suggesting that some life-threatening patients can elicit IgG4 to RBD antibody response in the first weeks of symptoms onset. Our findings constitute the effort to clarify IgG antibodies' kinetics, avidity, and subclasses against SARS-CoV-2 RBD in symptomatic patients with COVID-19 in Brazil, highlighting the importance of IgG antibody avidity in association with IgG4 detection as tool laboratory in the follow-up of hospitalized patients with more significant potential for life-threatening.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/42243
Referências
  1. Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
  2. Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
  3. Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9
  4. Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364
  5. Bachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024
  6. Bauer G, 2021, INT J INFECT DIS, V106, P61, DOI 10.1016/j.ijid.2021.01.061
  7. Benner SE, 2020, J INFECT DIS, V222, P1974, DOI 10.1093/infdis/jiaa581
  8. Bilich T, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf7517
  9. BOPPANA SB, 1995, J INFECT DIS, V171, P1115, DOI 10.1093/infdis/171.5.1115
  10. Cassaniti I, 2020, J MED VIROL, V92, P1724, DOI 10.1002/jmv.25800
  11. Castro R, 2020, BRAZ J INFECT DIS, V24, P180, DOI 10.1016/j.bjid.2020.04.003
  12. Cavacini LA, 2003, AIDS RES HUM RETROV, V19, P785, DOI 10.1089/088922203769232584
  13. Chan KH, 2007, CLIN VACCINE IMMUNOL, V14, P1433, DOI 10.1128/CVI.00056-07
  14. Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
  15. De Azevedo M. S. P., 2021, JMIR PUBLIC HLTH SUR
  16. Dobano C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10195-z
  17. Eisen HN, 2014, CANCER IMMUNOL RES, V2, P381, DOI 10.1158/2326-6066.CIR-14-0029
  18. Engin AB, 2020, ENVIRON TOXICOL PHAR, V78, DOI 10.1016/j.etap.2020.103411
  19. Felipe Rocha da Silva S, RES SQUARE, DOI [10.21203/rs.3.rs-402349/v2, DOI 10.21203/RS.3.RS-402349/V2]
  20. Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894
  21. Frasca D, 2017, CLIN EXP IMMUNOL, V187, P64, DOI 10.1111/cei.12824
  22. Frasca D, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-14
  23. Gaspar EB., 2021, HUM VACC IMMUNOTHER, DOI [10.1080/21645515.2021.1920272, DOI 10.1080/21645515.2021.1920272]
  24. Greiner M, 1996, J IMMUNOL METHODS, V191, P93, DOI 10.1016/0022-1759(96)00013-0
  25. Guan W.-J., 2002, CLIN CHARACTERISTICS
  26. Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
  27. Hsueh PR, 2004, CLIN MICROBIOL INFEC, V10, P1062, DOI 10.1111/j.1469-0691.2004.01009.x
  28. Huynh A., 2020, DEV SEROLOGICAL ASSA, V2009
  29. Iwasaki A, 2020, NAT REV IMMUNOL, V20, P339, DOI 10.1038/s41577-020-0321-6
  30. Jiang SB, 2020, TRENDS IMMUNOL, V41, P545, DOI 10.1016/j.it.2020.04.008
  31. JUNKER AK, 1994, J MED VIROL, V43, P119, DOI 10.1002/jmv.1890430204
  32. Kaneko M, 2017, J INFECT CHEMOTHER, V23, P173, DOI 10.1016/j.jiac.2016.12.001
  33. KAWANO Y, 1994, J IMMUNOL, V153, P4948
  34. Kellam P, 2020, J GEN VIROL, V101, P791, DOI 10.1099/jgv.0.001439
  35. Khatri I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.570018
  36. Kontio M, 2012, J INFECT DIS, V206, P1542, DOI 10.1093/infdis/jis568
  37. Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3
  38. Kweon OJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240395
  39. Lai L, 2007, VIROLOGY, V369, P153, DOI 10.1016/j.virol.2007.07.017
  40. Lazzarotto T, 2000, VIRAL IMMUNOL, V13, P137, DOI 10.1089/vim.2000.13.137
  41. Liu XM, 2020, EMERG MICROBES INFEC, V9, P1269, DOI 10.1080/22221751.2020.1773324
  42. Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
  43. Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
  44. MARTIN KA, 1994, J INFECT DIS, V170, P991, DOI 10.1093/infdis/170.4.991
  45. Mazzini L, 2021, J IMMUNOL METHODS, V489, DOI 10.1016/j.jim.2020.112937
  46. Menezes P. D. L., 2020, BRAZIL IS PROJECTED, DOI [10.1101/2020.04.28.20083675, DOI 10.1101/2020.04.28.20083675]
  47. Miot Hélio Amante, 2017, J. vasc. bras., V16, P88, DOI 10.1590/1677-5449.041117
  48. Nagao-Dias AT, 2007, BRAZ J INFECT DIS, V11, P215, DOI 10.1590/S1413-86702007000200009
  49. OMS, 2020, WHO COVID 19 WEEKL E, V1, P4
  50. Padoan A, 2020, CLIN CHEM LAB MED, V58, P1081, DOI 10.1515/cclm-2020-0443
  51. Pegu P, 2013, J VIROL, V87, P1708, DOI 10.1128/JVI.02544-12
  52. Nguyen-Contant P, 2020, MBIO, V11, DOI 10.1128/mBio.01991-20
  53. Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1
  54. PULLEN GR, 1986, J IMMUNOL METHODS, V86, P83, DOI 10.1016/0022-1759(86)90268-1
  55. Puschnik A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002274
  56. Rai P, 2021, APPL MICROBIOL BIOT, V105, P441, DOI 10.1007/s00253-020-11061-5
  57. Rebello CJ, 2020, INT J OBESITY, V44, P1810, DOI 10.1038/s41366-020-0640-5
  58. Ribas RM, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101675
  59. Santana SS, 2012, IMMUNOL LETT, V143, P193, DOI 10.1016/j.imlet.2012.02.008
  60. Satoguina JS, 2005, J IMMUNOL, V174, P4718, DOI 10.4049/jimmunol.174.8.4718
  61. Scohy A, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104455
  62. Seo S, 2009, KOREAN J LAB MED, V29, P557, DOI 10.3343/kjlm.2009.29.6.557
  63. Shih HI, 2020, BIOMED J, V43, P341, DOI 10.1016/j.bj.2020.05.021
  64. Siracusano G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01049
  65. Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
  66. Stromer A., 2020, DIAGNOSTIC ACCURACY, V2015
  67. Suthar MS, 2020, CELL REP MED, V1, DOI [10.1016/j.xcrm.2020.100040, 10.1101/2020.05.03.20084442]
  68. Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
  69. Valdivia A, 2021, J MED VIROL, V93, P1141, DOI 10.1002/jmv.26344
  70. Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]
  71. Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906
  72. Wang P, 2020, J VIROL METHODS, V283, DOI 10.1016/j.jviromet.2020.113919
  73. Ward S, 2020, J ALLERGY CLIN IMMUN, V146, P23, DOI 10.1016/j.jaci.2020.05.012
  74. Wolf J, 2020, CLIN CHIM ACTA, V511, P352, DOI 10.1016/j.cca.2020.10.035
  75. Wolfel R, 2020, NATURE, V588, pE35, DOI [10.1159/000505601, 10.1038/s41586-020-2984-3, 10.1038/s41586-020-2196-x]
  76. World Health Organization, 2020, LAB BIOS GUID REL CO
  77. Yang HS, 2020, CLIN CHIM ACTA, V509, P117, DOI 10.1016/j.cca.2020.06.004
  78. Zhang JJ, 2021, ALLERGY, V76, P533, DOI [10.1111/all.14238, 10.1111/all.14496]
  79. Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4
  80. Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344
  81. Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - LIM/49
Artigos e Materiais de Revistas Científicas - ODS/03